Business Context and Reporting Period
Company: Rand Capital Corporation (Rand)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2012
Rand Capital Corporation is a publicly traded Business Development Company (BDC) registered under the Investment Company Act of 1940. It operates a wholly-owned subsidiary, Rand Capital SBIC, Inc., which is licensed by the U.S. Small Business Administration (SBA) as a Small Business Investment Company (SBIC). The Corporation invests in a portfolio of debt and equity securities of small and middle-market companies.
Key Financial Metrics
| Metric | Amount (Nine Months Ended Sep 30, 2012) | Amount (Nine Months Ended Sep 30, 2011) |
|---|---|---|
| Total Investment Income | $2,185,292 | $916,290 |
| Total Expenses | $1,202,052 | $1,301,529 |
| Net Investment Gain | $767,920 | ($265,761) |
| Net Realized Gain on Investments | $258,590 | ($1,322,563) |
| Net Increase in Unrealized Appreciation | $660,279 | $2,372,253 |
| Net Increase in Net Assets from Operations | $1,686,789 | $783,929 |
| Cash and Cash Equivalents | $4,042,981 | $4,504,418 |
| Total Investments (Fair Value) | $27,810,532 | $23,931,861 |
| SBA Debentures Outstanding | $3,900,000 | $4,000,000 |
| Net Assets (Stockholders' Equity) | $25,928,752 | $24,399,121 |
| Net Asset Value (NAV) per Share | $3.84 | $3.58 |
Material Changes vs. Prior Period
- Investment Income Surge: Total investment income increased 138.5% to $2.19 million, driven primarily by a 437.4% increase in dividend and other investment income. This was largely due to a $1.56 million distribution from Gemcor II, LLC. Conversely, interest income from portfolio companies decreased 22.5% due to debt-to-equity conversions in prior periods and the cessation of interest accrual on the EmergingMed.com investment.
- Expense Reduction: Total operating expenses decreased 7.6% to $1.20 million. This was primarily due to a 73% reduction in SBA interest expense following the repayment of higher-rate debt and the drawdown of lower-rate leverage. This was partially offset by a $144,000 accrual for profit sharing bonuses.
- Portfolio Valuation: Total investments at fair value increased 16.2% to $27.8 million. Net unrealized appreciation increased by $1.14 million, driven by mark-to-market gains on Synacor, Inc. (following its IPO) and Liazon Corporation, partially offset by write-downs on Ultra-Scan Corporation and EmergingMed.com.
- Realized Gains: The Company recognized a net realized gain of $258,590, primarily from the sale of Synacor, Inc. shares, compared to a net realized loss of $1.32 million in the prior year.
Outlook, Risks, and Management Commentary
- Capital Resources: The Company maintains $4.04 million in cash and cash equivalents. It has $3.9 million in outstanding SBA leverage and $5.0 million in remaining SBA commitment capacity. Management expects current liquidity and available leverage to be sufficient for the next 12 months.
- Subsequent Events: Following the quarter-end, the Company drew down an additional $1 million in SBA leverage, made two new investments totaling $1.2 million, and repurchased 144,208 shares of common stock. The stock buyback program was extended through November 1, 2013.
- Valuation Risk: A significant portion of the portfolio (77%) consists of Level 3 assets (restricted securities) valued using unobservable inputs. Management noted that the value of its Synacor, Inc. holding decreased by approximately $1.21 million in the weeks following the quarter-end due to market price fluctuations, which could materially impact future NAV.
- Profit Sharing: The Company accrued $144,000 in profit sharing obligations for the nine months ended September 30, 2012, based on the performance of its SBIC subsidiary.
Investor Verification Checklist
- Synacor Valuation Volatility: Verify the current market price of Synacor, Inc. (SYNC) shares, as a significant portion of the portfolio's unrealized gain is tied to this single holding, which experienced a post-quarter decline.
- Interest Accrual Status: Confirm the status of the EmergingMed.com investment, on which the Company ceased accruing interest in Q3 2012, and monitor for potential future write-downs.
- SBA Leverage Terms: Review the specific interest rates and maturity dates of the new $3 million SBA drawdown (3% rate, maturing 2022) versus the remaining older debt to assess future interest expense.
- Portfolio Concentration: Note that Gemcor II, LLC and Synacor, Inc. represent 30% and 23% of the portfolio's fair value, respectively, creating concentration risk.
- Stock Repurchase Activity: Monitor the execution of the extended stock buyback program, which aims to accumulate up to 500,000 shares.